Baird lowered the firm’s price target on Karyopharm (KPTI) to $25 from $42 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which showed its MF Phase 3 enrollment is early complete.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI: